GlassScriptPhysician profile
Thomas Hand
NPI 1831517572
$78,168.73
in general payments reported to CMS, 2019-2025
30 companies · $9,899 in 2025
The $9,899 reported for 2025 was more than what 87% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,207 · 2020: $2,224 · 2021: $3,002 · 2022: $6,798 · 2023: $36K · 2024: $11K · 2025: $9,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $33K · Travel and Lodging: $13K · Food and Beverage: $7,433 · Consulting Fee: $4,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $32,548.06 |
| Travel and Lodging | $12,956.75 |
| Food and Beverage | $7,432.63 |
| Consulting Fee | $4,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New Standard Device, LLC Dba Metalogix | $32,548.06 | 2023 | |
| Stryker Corporation | $8,217.73 | 2019-2025 | T2 Alpha, Augment Injectable, Axsos |
| Bonebridge INC. | $7,786.74 | 2024 | |
| Smith+Nephew, INC. | $6,152.34 | 2020-2025 | Evos, Trigen Intertan, Trigen |
| Sanara Medtech INC. | $5,840.98 | 2021-2025 | Celleraterx, Biasurge, Celleraterx |
| Arthrex, INC. | $5,000.00 | 2019 | |
| Kci USA, INC. | $3,187.50 | 2022 | |
| Depuy Synthes Sales INC. | $1,710.75 | 2019-2025 | Na, Tfn-Advance, Va-Lcp |
| Musculoskeletal Transplant Foundation INC. | $1,219.57 | 2023-2025 | |
| Acumed LLC | $987.06 | 2019 | |
| Zimmer Biomet Holdings, INC. | $861.53 | 2022-2023 | Avenir, Affixus |
| Osteocentric Technologies, INC. | $808.42 | 2020-2024 | Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St |
| Bioventus LLC | $680.58 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Si-Bone, INC. | $564.25 | 2020-2025 | |
| Integra Lifesciences Corporation | $481.82 | 2020-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bone Support INC. | $288.43 | 2020-2022 | |
| Globus Medical, INC. | $273.02 | 2019 | |
| Acell, INC. | $225.62 | 2019 | |
| Medline Industries LP | $156.68 | 2022 | |
| Medela LLC | $153.97 | 2019 | |
| Ethicon US, LLC | $127.49 | 2021 | |
| Medtronic, INC. | $126.55 | 2021 | |
| Kerecis Limited | $125.68 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Acera Surgical, INC. | $125.45 | 2023 | Restrata Wound Matrix |
| Djo, LLC | $112.50 | 2020 | |
| Bausch & Lomb Americas INC. | $106.06 | 2025 | Xiidra, Miebo |
| Axogen | $105.77 | 2019 | |
| Skeletal Dynamics INC | $104.19 | 2019 | |
| Medinc of Texas | $67.43 | 2022-2023 | |
| Mission Medical Distribution, LLC | $22.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.